Ingram D V, Jaggarao N S, Chamberlain D A
Br J Ophthalmol. 1982 Oct;66(10):676-9. doi: 10.1136/bjo.66.10.676.
Amiodarone, a powerful antiarrhythmic agent recently made available in Britain, is known to cause corneal changes, but the clinical implications of this unwanted effect are still controversial. We have made serial observations on 105 patients treated with the drug for periods ranging from 3 months to over 7 years. Corneal abnormalities were detected by slit-lamp examination in 103 patients (98%). These always progressed over several months but subsequently showed a stable pattern which changed only with alteration of dose. The abnormalities regressed and disappeared within 7 months in the 16 patients whose treatment was discontinued for reasons unconnected with ocular changes. No macular changes or permanent sequelae occurred. Ocular symptoms were unusual: 6 patients had reactions in the skin of the eyelids, and 6 others had minor symptoms related to the corneal changes. We do not believe that ophthalmological surveillance is mandatory in asymptomatic patients on long-term amiodarone therapy.
胺碘酮是一种最近在英国上市的强效抗心律失常药物,已知会引起角膜改变,但其这种不良作用的临床意义仍存在争议。我们对105例接受该药治疗3个月至7年以上的患者进行了连续观察。通过裂隙灯检查在103例患者(98%)中检测到角膜异常。这些异常总是在几个月内进展,但随后呈现出稳定的模式,仅随剂量改变而变化。在16例因与眼部变化无关的原因停药的患者中,异常在7个月内消退并消失。未出现黄斑改变或永久性后遗症。眼部症状不常见:6例患者眼睑皮肤有反应,另外6例有与角膜改变相关的轻微症状。我们认为,对于长期接受胺碘酮治疗的无症状患者,并非必须进行眼科监测。